Immuneel Therapeutics Raises ₹100 Crore: The Indian Biotech Startup Bringing Next-Generation Cancer Treatment to the World

Backed by Kiran Mazumdar-Shaw, Immuneel Is Scaling India’s First Homegrown CAR-T Therapy and Building a Global Cell & Gene Therapy Powerhouse

Cancer remains one of humanity’s greatest healthcare challenges.

Despite decades of medical innovation, millions of patients worldwide still struggle to access advanced treatments due to high costs, limited infrastructure, and unequal healthcare access. While groundbreaking therapies such as CAR-T cell therapy have transformed cancer treatment outcomes in developed markets, their adoption in emerging economies has remained limited because of affordability concerns.

A Bengaluru-based biotechnology company is now working to change that reality.

Immuneel Therapeutics, India’s pioneering cell and gene therapy company, has successfully raised over ₹100 crore in Series B funding, marking one of the most significant biotech funding announcements of 2026. The investment comes at a critical time when global healthcare systems are increasingly embracing personalized medicine and advanced immunotherapy solutions.

The funding round attracted participation from Singularity AMC, Rainmatter by Zerodha, several high-net-worth investors, and existing backers including Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital. The fresh capital will help the company expand manufacturing capacity, accelerate commercialization of its CAR-T therapy, strengthen its research pipeline, and drive international expansion across Asia-Pacific and Middle Eastern markets.

For India’s biotechnology sector, this funding round is far more than a financial milestone.

It represents growing confidence in India’s ability to develop world-class cancer therapies, compete globally in advanced biotechnology, and make life-saving treatments more accessible for patients worldwide.

The Vision Behind Immuneel Therapeutics

Founded in Bengaluru and co-founded by biotech entrepreneur Kiran Mazumdar-Shaw, Immuneel was created with a clear mission: to make advanced cell and gene therapies accessible and affordable for cancer patients in India and beyond.

The company operates in one of the most advanced fields of modern medicine—Cell and Gene Therapy (CGT).

Unlike traditional cancer treatments such as chemotherapy and radiation therapy, cell therapies leverage a patient’s own immune system to identify and destroy cancer cells. These therapies are highly personalized and have demonstrated remarkable outcomes in patients who have exhausted conventional treatment options.

Among these innovations, CAR-T (Chimeric Antigen Receptor T-Cell) Therapy is considered one of the most revolutionary breakthroughs in oncology.

CAR-T therapy involves collecting a patient’s T-cells, genetically modifying them to recognize cancer cells, and then reintroducing them into the body to fight the disease more effectively. The treatment essentially transforms the patient’s own immune cells into targeted cancer-fighting agents.

While CAR-T therapies have delivered exceptional results globally, they often cost hundreds of thousands of dollars in international markets.

Immuneel’s objective is to significantly reduce those costs while maintaining global quality standards.

The ₹100 Crore Series B Funding Round

The company’s latest funding round has become one of the biggest healthcare startup stories of 2026.

Immuneel secured more than ₹100 crore from a mix of institutional investors and existing stakeholders. The investment demonstrates strong confidence in both the company’s technology platform and its long-term commercial potential.

According to the company, the newly raised capital will be used to:

• Expand GMP manufacturing infrastructure
• Accelerate commercialization of Qartemi
• Advance next-generation cell and gene therapies
• Support clinical research programs
• Expand globally across Asia-Pacific and the Middle East
• Strengthen operational and scientific capabilities

The funding arrives at a pivotal moment as Immuneel transitions from a clinical-stage innovator into a commercial biotechnology company with global ambitions.

Qartemi: India’s Breakthrough CAR-T Therapy

One of Immuneel’s most significant achievements has been the launch of Qartemi, India’s indigenous CAR-T therapy developed for adult patients suffering from specific forms of blood cancer, particularly B-cell Non-Hodgkin Lymphoma.

Qartemi represents a major milestone for India’s healthcare ecosystem.

Historically, patients requiring advanced CAR-T treatments often had to rely on imported therapies that were prohibitively expensive. Immuneel’s solution has demonstrated that advanced immunotherapies can be developed, manufactured, and delivered within India while remaining more affordable than many global alternatives.

The therapy has already generated significant interest among oncologists and healthcare institutions.

Major hospital networks including Apollo Hospitals, Narayana Health, Manipal Hospitals, and CMC Vellore have collaborated with Immuneel to expand patient access to this breakthrough treatment.

Recent Developments Driving Momentum

Over the past three months, Immuneel has continued to strengthen its position within the biotechnology sector.

The company received recognition as the ABLE BioInnovator of the Year 2026, acknowledging its contribution to advancing India’s biotechnology ecosystem and personalized cancer care. The award highlighted the impact of Qartemi and Immuneel’s role in making advanced therapies more accessible.

Additionally, the company has reported encouraging long-term clinical outcomes for patients treated with its CAR-T therapies, further reinforcing confidence among clinicians, investors, and regulators.

Immuneel has also been actively engaging with the global scientific community through industry conferences, oncology forums, and cellular therapy events, demonstrating its commitment to research and innovation.

These developments are helping establish the company as one of India’s leading biotechnology innovators.

Why Investors Are Paying Attention

The global biotechnology industry is undergoing a profound transformation.

Advancements in personalized medicine, genetic engineering, immunotherapy, and cell-based treatments are creating entirely new categories of healthcare innovation.

Investors see Immuneel as uniquely positioned within several high-growth sectors.

1. Massive Market Opportunity

Cancer continues to be one of the leading causes of death worldwide. As healthcare systems increasingly adopt personalized treatment approaches, demand for advanced therapies is expected to grow significantly over the next decade.

2. Commercial Validation

Unlike many biotech startups still operating solely in research phases, Immuneel has already commercialized a CAR-T therapy. This reduces execution risk and provides a clearer path toward revenue generation.

3. Cost Advantage

Immuneel’s ability to develop and manufacture therapies within India creates substantial cost advantages compared to Western markets, opening opportunities across emerging economies.

4. Global Expansion Potential

The company is actively targeting Asia-Pacific and Middle Eastern markets, regions where access to advanced cancer therapies remains limited but demand continues to grow.

Building a Global Biotechnology Brand

While India remains Immuneel’s primary market, the company’s ambitions extend far beyond national borders.

Management has identified international expansion as a key strategic priority.

The new funding will support regulatory approvals, commercial partnerships, and operational expansion across multiple geographies. This international focus positions Immuneel to become not just an Indian success story but a globally recognized biotechnology company.

As healthcare systems worldwide seek more affordable alternatives to expensive imported therapies, Immuneel’s model could become increasingly attractive.

The Future of Cancer Care

The future of oncology is shifting toward precision medicine and personalized therapies.

Traditional one-size-fits-all treatments are gradually being replaced by targeted approaches designed specifically for individual patients and disease profiles.

Cell and gene therapies are expected to play a central role in this transformation.

Immuneel is positioning itself at the forefront of this movement.

With fresh funding, a commercially validated therapy, expanding manufacturing capabilities, and a growing global presence, the company is entering the most important phase of its journey.

Final Thoughts

Immuneel Therapeutics is no longer just a promising biotech startup.

It is rapidly emerging as one of India’s most important healthcare innovation companies.

The successful ₹100+ crore Series B funding round validates the company’s vision, technology, and long-term potential. More importantly, it highlights the growing maturity of India’s biotechnology ecosystem and its ability to create globally competitive healthcare solutions.

As Immuneel scales Qartemi, advances next-generation therapies, and expands internationally, it has the potential to transform how advanced cancer treatments are delivered across emerging markets.

If successful, the company won’t simply make cancer therapies more affordable.

It could redefine India’s role in the future of global biotechnology.